Skip to main content

RxSight Inc

For the period ended Dec 31, 2023. Filed Feb 28, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 28, 2024

RXST$4.86+7.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 16. Form 10-K Summary

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

RxSight, Inc.
Date: February 28, 2024By:/s/ Ron Kurtz, M.D.
Ron Kurtz, M.D.
Chief Executive Officer
(Principal Executive Officer)

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Ron Kurtz, M.D. and Shelley Thunen as such individual’s true and lawful attorney in fact and agent with full power of substitution, for such individual in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney in fact, proxy and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney in fact, proxy and agent, or the individual’s substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

NameTitleDate
/s/ Ron Kurtz, M.D.President and Chief Executive Officer and DirectorFebruary 28, 2024
Ron Kurtz, M.D.(Principal Executive Officer)
/s/ Shelley ThunenChief Financial OfficerFebruary 28, 2024
Shelley Thunen(Principal Financial and Accounting Officer)
/s/ J. Andy CorleyChairman of the BoardFebruary 28, 2024
J. Andy Corley
/s/ William Link, Ph.D.DirectorFebruary 28, 2024
William Link, Ph.D.
/s/ Juliet Tammenoms BakkerDirectorFebruary 28, 2024
Juliet Tammenoms Bakker
/s/ Julie AndrewsDirectorFebruary 28, 2024
Julie Andrews
/s/ Robert PalmisanoDirectorFebruary 28, 2024
Robert Palmisano
/s/ Robert WarnerDirectorFebruary 28, 2024
Robert Warner
/s/ Shweta Singh ManiarDirectorFebruary 28, 2024
Shweta Singh Maniar
/s/ Tamara R. Fountain, M.D.DirectorFebruary 28, 2024
Tamara R. Fountain, M.D.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.